Intramyocardial transplantation of circulating CD34+ cells: source of stem cells for myocardial regeneration. by Kim, Yong-Hwan
INTRODUCTION
Tissue ischemia was found to mobilize CD34+ cells from
the bone marrow into the peripheral blood in an animal model
(1), and circulating CD34+ counts significantly increased in
patients with acute myocardial infarction (MI) (2). However,
an optimum method for harvesting CD34+cells in acute MI
has not yet been determined.
After acute MI, cardiomyocytes are damaged and are grad-
ually replaced by fibrosis and scar formation, which leads to
the loss of regional contractile function (3). The source of cells
used for transplantation into infarcted myocardium varies, e.g.,
cardiomyocytes (4), skeletal muscle cells (5), smooth muscle
cells (6), and bone marrow mononuclear cells (7). A previous
study reported that CD34+ cells were incorporated into the
border of infarcted myocardium (1), which suggests that they
may be used in cell transplantation for infarcted myocardium.
The purpose of this study was to propose the optimal me-
thod of harvesting circulating CD34+ cells and to evaluate
the potential roles of CD34+ cells in regeneration of infarct-
ed myocardium. 
MATERIALS AND METHODS
Experimental Animals 
All surgical procedures were performed under general anes-
thesia with electrocardiographic monitoring. Anesthesia for
ligating the left anterior descending coronary artery (LAD)
was induced and maintained with isoflurane. The anesthetized
rats were intubated, and were maintained on positive-pressure
ventilation. Rat hearts were exposed through 2 cm left lateral
thoracotomy. The rats for sacrifice were anesthetized with ke-
tamine hydrochloride (25 mg/kg) and xylazine (3 mg/kg).
The muscle layer and skin incisions were closed with 5-0
Vicryl sutures. Penicillin G benzathine (150,000 U/mL) was
given intramuscularly (0.25 mL per rat) once in every 3 days
for 1 week postoperatively, and buprenorpine hydrochloride
(0.02 mg/kg) was administered subcutaneously once in every
12 hr for the first 48 hr after the operation.
Experimental Donor Groups
In this study, donor rats were categorized into 5 groups: MI,
sham, granulocyte-colony stimulating factor (GCSF), MI+
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Intramyocardial Transplantation of Circulating CD34+ cells:
Source of Stem Cells for Myocardial Regeneration
This study was designed to investigate the increase in the number of circulating
CD34+ cells after acute myocardial infarction (MI) and the differentiation of these
cells to cardiomyocytes after transplantation into infarcted myocardium. The study
involved five donor groups: MI (n=27), sham (n=26), granulocyte-colony stimulating
factor (GCSF) (n=26), MI+GCSF (n=25), and control (n=25). Acute MI was induced
by ligating the left anterior descending coronary arteries (LAD) of donor rats, and
LAD of recipient rats were ligated on the same day. Seven days after ligation, CD34+
cells in donor rats were counted and then were directly injected into the infarcted
myocardium of recipient rats. Eight weeks after the transplantation, significant differ-
ences (p<0.001) were observed in the CD34+cell counts among the 5 donor groups
with the greatest increase in the MI+GCSF donor group. In rats receiving CD34+
cells, the size of the scar area smaller (p<0.001) and the thickness of the scar was
greater (p=0.001) than in CD34- and saline-transplanted rats. The transplanted
CD34+ cells differentiated into cardiomyocytes in the scar. This study suggests that
CD34+ cells may be a potential source of stem cells and that they may be useful
in strategies aimed at the regeneration of infarcted myocardium.
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GCSF, and control rats. Acute MI was induced by ligating the
proximal LAD with 6-0 prolene sutures (MI group; n=27).
Seven days after ligation, the whole peripheral blood of each
donor rat was obtained from the aorta through a mid-abdom-
inal incision. Cells were suspended in phosphate-buffered
saline (PBS) after red blood cell lysis and incubated for 15 min
at 4℃ with anti-CD34 antibody (Miltenyi Biotec, Auburn,
CA, U.S.A.). After PBS wash, the cells were loaded onto a
Midi-MACS column (Miltenyi) held within a magnetic field
to retain CD34+ cells. Unbound cells were eluted with PBS
and the retained CD34+ cells were eluted by washing with
PBS after the column had been removed from the magnet.
After isolaton, CD34-cells were also collected for cell trans-
plantation. CD34+ cells were counted by microscopic enu-
meration with a cell-counting hematocytometer (Hausser
scientific, Horsham, PA, U.S.A.). Investigators were unaware
of which group the cells had been assigned. Rats that under-
went the same procedure in the MI group, except for induc-
tion of acute MI were assigned to the sham group (n=26). The
rats in the GCSF group (n= 26) received GCSF subcutaneously
at 40  g/kg/day for 4 days before cell counting. In the MI+
GCSF group (n=25), GCSF was administered as in the GCSF
group after inducing MI. The LAD was not ligated, neither
GCSF was administered in the control group (n=25).
Experimental Recipient Groups
The LAD of recipient rats was ligated on the same day as in
the donor rats. Seven days after ligation, 3 different substances
were transplanted into the acute infarcted myocardium of the
recipients rats: CD34+ cells (n=20), CD34-cells (n=20), or
saline (n=10). CD34+ cells and CD34-cells were obtained
from the donor rats.
Cell Labeling and Cell Transplantation
To identify the transplanted cells, CD34+cells and CD34-
cells were labeled with PKH26 (Sigma-Aldrich, St. Louis,
MO, U.S.A.) just before transplantation. CD34+and CD34-
cells were suspended in PBS (200  L, 2×106 cells) and were
injected into several sites in the acute infarcted myocardium
with a 28-gauge needle. Half of the suspension was delivered
into the center of the infarct, and the other half was divided
into 4 or 5 injections at the periphery of the infarct zone, to
facilitate potential interaction between the transplanted cells
and the normal myocardium. The transplanted zone was mac-
roscopically identified by the pale color of the ischemic territory.
Measurement of Remodeling and Histologic Studies 
The recipient rats were killed 8 weeks after transplantation.
Their hearts were quickly excised, and the atria were removed.
The hearts were fixed with 10% phosphate-buffered formalin
and then cut into 3 sections of 5 mm thickness. Each section
was then embedded in paraffin and sectioned to yield 10  m
slices. The slices were then stained with hematoxylin and eosin.
For histological studies of each section, the thickened scar was
measured at the center. The areas of normal tissue, scar tis-
sue, and transplanted tissue in the left ventricular free wall
(LVFW) were quantified by computed planimetry (Jandal
Scientific Sigma-Scan, Corte Madera, CA, U.S.A.) (4, 8, 9).
The lengths of the LVFW and the scar tissue on both the endo-
cardial and epicardial surface of each section were measured.
The surface areas of the epicardial and endocardial scar tissue
and the LVFW were measured as the sum of the endocardial
length and epicardial length multiplied by the thickness of
section (5 mm). The percentage of surface area of scar tissue
in the LVFW was calculated as follows:
(epicardial scar size+endocardial scar size)/(epicardial LVFW
+endocardial LVFW)×100.
To calculate the percentage of the surface area in the scar
tissue occupied by transplanted tissue, the transplanted tissue
length in the scar tissue of each section multiplied by the thick-
ness of the section (5 mm) was added and then divided by the
total scar area multiplied by 100.
For immunohistochemical studies, tissue slices were serially
rehydrated in 100%, 90%, 70%, and 50% ethanol after de-
paraffinization with xylene. The samples were stained with
antibodies against Troponin T-C (Santa Cruz Biotechnology,
Santa Cruz, CA, U.S.A.) to identify transplanted cells that
had differentiated into cardiomyocytes in the scar area (10).
Statistical Analysis
All data are presented as means±SD. SPSS for Windows
(version 10.0) was used for all analyses. One way analysis of
variance (ANOVA) followed by the Schffe’s test was used to
compare the body weights and the CD34+cell levels in the
5 donor groups. The comparisons between the recipient groups
in terms of body weight, scar area, and scar thickness were
conducted by ANOVA. A significance level of 0.05 was used
for group comparison.
RESULTS
Body Weight of Rats
The body weights of the 5 donor groups and 3 recipient
groups are shown in Table 1. No significant differences were
observed among the donor groups (p=0.995) or among the 3
recipient groups (p=0.399).
Number of Circulating CD34+ Cells
The median number of CD34+cells before MACS was 2.7
×108/mL of whole blood (range, 1.2-3.5) in MI, 2.3 (range,CD34+ Cells for Myocardial Regeneration 799
0.9-3.4) in sham, 2.9 (1.2-3.5) in GCSF, 3.0 (1.4-3.8) in MI+
GCSF, and 2.2 (0.9-3.3) in control. The CD34+ cell count
(106 cells/mL of whole blood) demonstrated significant dif-
ferences (p<0.001) among the 5 donor groups (Table 2): MI
(mean±SD, 0.29±0.05, range, 0.20-0.40), sham (0.15±
0.04, 0.05-0.22), GCSF (0.50±0.06, 0.40-0.59), MI+GCSF
(0.87±0.06, 0.74-0.98), and control (0.14±0.04, 0.06-
0.20). However, no significant differences were found between
the control and sham groups in terms of cell count (p=0.98).
A greater increase was found in the number of CD34+cells in
the MI group than in the sham group or in the control group
(p<0.001). In addition, circulating CD34+ cells increased
more in the GCSF group than in the MI group (p< 0.001);
and the increase of the CD34+ cells was the greatest in the
MI+GCSF group (MI+GCSF vs. GCSF, p<0.001), which was
about 3 times higher than that in the MI group.
Morphometric studies
The comparisons of the scar size demonstrated significant
differences (p<0.001) among the 3 recipient group (Table 3).
The size of the scar was smaller in the CD34+injection group
than in the CD34- or saline injection group (CD34+ vs.
CD34-, p=0.002; CD34+vs. saline, p=0.001). However, the
size was not significantly different between the CD34- and
saline injection groups (p=0.524).
The comparisons of the thickness of the scar also demonstrat-
ed significant differences (p=0.001) among the 3 recipient
groups (Table 4); the thickness of the scar was greater in the
CD34+injection group than in the CD34-or saline injection
group (CD34+ vs. CD34-, p=0.003; CD34+ vs. saline, p=
0.011), though no significant difference was found between
the CD34-and saline injection groups (p=0.976).
Histologic studies
The scar in the control heart was larger and thinner than
that in the heart after transplantation (Fig. 1A-D). Histologic
evaluation of myocardial sections stained with hematoxylin
and eosin demonstrated the transplanted CD34+cells existed
in islands in the myocardial scar tissue, suggesting that they
might have differentiated into the cardiomyocytes (Fig. 1E).
Eight weeks after cell transplantation, the cells labeled with
PKH were identified within the infarct zone of CD34+ cell
transplanted hearts (Fig. 2A). In addition, a large portion of
CD34+cells labeled with PKH26 stained positively for Tro-
ponin T-C (Fig. 2B). This finding indicates that the CD34+
cells may differentiate into cardiomyocytes in the scar of the
recipient myocardium in vivo. However, no newly formed
MI, myocardial infarction; GCSF, granulocyte colony stimulating factor;
MI+GCSF, GCSF injection after induction of MI.
*
,� Not significantly different among the 5 donor and 3 recipient groups.
Group No. Body weight (g) p value
Donor Group
MI 27 274.9±13.97 0.995*
Sham 26 276.3±14.15
GCSF 26 275.3±13.90
MI+GCSF 25 276.0±14.16
Control 25 276.1±14.17
Recipient Group
CD34+ 20 279.7±11.54 0.399
�
CD34- 20 275.5±11.90
Saline 10 274.7±9.98
Table 1. Body weights in donor rats and recipient rats
MI, myocardial infarction; GCSF, granulocyte colony stimulating factor
MI+GCSF, GCSF injection after inducing MI.
*Significantly different among the 5 donor groups. 
� Not significantly differ-
ent between the sham and the control groups (p=0.98). 
� A greater in-
crease was found in the MI group than in the sham group or in the con-
trol group (p<0.001). 
�Significantly different between the MI and the GCSF
groups (p<0.001). 
‖Significantly different between the GCSF and the
MI+GCSF groups (p<0.001).
Group No.
Cell count (10
6 cells/mL of
whole blood)
p value*
MI 27 0.29±0.05
� ,� <0.001
Sham 26 0.15±0.04
� ,�
GCSF 26 0.50±0.06
�,‖
MI+GCSF 25 0.87±0.06
‖
Control 25 0.14±0.04
� ,�
Table 2. Comparisons of CD34+ cell counts among 5 donor
groups
*Significantly different among the 3 recipient groups. 
� Significantly different
between the CD34+ and the CD34- cell transplantation groups (p=0.002).
� Significantly different between the CD34+ and the saline transplantation
groups (p=0.001). 
�Not significant between the CD34- and the saline
transplantation groups (p=0.524).
Group No. Scar size (%) p value*
CD34+ 20 19.7±3.08
� ,� <0.001
CD34- 20 22.6±2.23
� ,�
Saline 10 23.7±1.25
� ,�
Table 3. Comparisons of the scar size in recipient rats after trans-
plantation
*Significantly different among the 3 recipient groups. 
� Significantly differ-
ent between the CD34+ and the CD34- transplantation groups (p=0.003).
� Significantly different between the CD34+ and the saline transplantation
groups (p=0.011). 
�Not significantly different between the CD34- and
the saline transplantation groups (p=0.976).
Group No. Scar thickness (mm) p value*
CD34+ 20 1.09±0.18
� ,� =0.001
CD34- 20 0.89±0.17
� ,�
Saline 10 0.87±0.19
� ,�
Table 4. The thickness comparisons of scar in transplanted re-
cipient rats800 Y.-H. Kim
Fig. 1. Photographs of rat hearts from the control (A) and transplan-
tation (B) groups 8 weeks after the ligation of the left anterior des-
cending artery. The transmural scar tissue in the control heart (C)
is larger and thinner than that of the heart after transplantation (D).
Black arrow indicates the region of the microscopic examination.
The transplanted CD34+ cells might have differentiated into car-
diomyocytes (T) in the scar tissue (S) (E) (E: H&E, ×100) (M=nor-
mal myocardium).
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cardiac tissue was present in CD34-cell transplanted hearts.
DISCUSSION
A previous study reported that the number of circulating
CD34+ cells was significantly increased in patients with acute
MI, whereas it remained unchanged in control subjects who
had no evidence of cardiac ischemia (2). Russel et al. (11) re-
ported that the number of CD34+ cells was increased by 4-
5 times after mobilization with GCSF. However, the optimal
method of harvesting CD34+ cells has not been determined.
To harvest CD34+ cells, this study involved 5 donor groups:
MI, sham, GCSF, MI+GCSF, and a controlas group. The num-
ber of CD34+ cells was higher in the MI group than in the
control or in the sham group (p<0.001). In addition, a greater
number of the cells were present in the GCSF group than in
the MI group (p<0.001), and in MI+GCSF group than in the
GCSF group (p<0.001). The MI+GCSF cell count was about
3 times higher than the MI cell count.
Asahara and colleagues (12) reported that CD34+ cells, as
putative endothelial precursor cells (EPCs), were isolated from
human peripheral blood by magnetic bead selection by cell
surface antigen expression and were differentiated into mature
endothelial cells in vitro. In addition, Asahara et al. (1) demon-
strated incorporation of EPCs into the foci of neovasculariza-
tion at the border of the myocardial infarction. After tissue
ischemia, CD34+cells were mobilized from the bone marrow
and were incorporated into neovascularization sites. These
findings are consistent with the fundamental notions in the
postnatal vasculogenesis of CD34+cells. In addition, the role
of CD34+ cells in this pathophysiological response to tissue
ischemia may provide strategies for the regeneration of infarct-
ed myocardium.
Although the intravenous infusion of CD34+ cells may be
systemically easier and simpler than direct myocardial injec-
tion, a large number of CD34+ cells are required in the for-
mer (13). Therefore, the present study was performed to deter-
mine whether this shortcoming could be circumvented by
delivering cells directly to the ischemic myocardium. In addi-
tion, cryoinjury is often used experimentally to produce myo-
cardial necrosis and subsequent scar formation because the
transmural scar is more constant in size, and the myocardial
dysfunction is less variable than that seen after coronary ligation
(14, 15). However, myocardial injury resulting from cryoinjury
has limited clinical relevance. Therefore, coronary ligation was
selected in this study to induce myocardial ischemia.
Troponin T-C reacts with the cardiac muscle in mouse, rat,
and human. However, no cross-reaction was observed in fast
skeletal muscle or slow skeletal muscle (10). In the present
study, a large portion of CD34+ cells labeled with PKH26
stained positively for Troponin T-C. This finding indicates
that the CD34+ cells may differentiate into cardiomyocytes
in the scar of recipient myocardium in vivo. 
The size of scar was smaller in the CD34 injection group
than in the CD34- or saline injection group (Table 3). The
thickness of the scar was greater in the CD34+injection group
than in the CD34- or saline injection group (Table 4). The
Fig. 2. (A) Representative fluorescence microscopic findings of the recipient ischemic myocardium 8 weeks after CD34+ cell transplanta-
tion. Red fluorescence indicates CD34+ cells labeled with PKH26 just before transplantation (×100). (B) Representative immunohistochem-
ical findings for Troponin T-C in the recipient ischemic myocardium 8 weeks after CD34+ cell transplantation. Green fluorescence indicates
Troponin T-C binding. A large portion of CD34+ cells labeled with PKH26 stained positively for Troponin T-C (×100). 
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possible mechanism of the reducing the scar size and increas-
ing the scar thickness in the CD34+ cell transplantation is
that the CD34+cells may differentiate into cardiomyocytes
and these cardiomyocytes would prevent fibroblast stretching
and ventricular enlargement. 
According to manufacturer, the CD34+ cells in peripheral
blood can be enriched to a purity of about 85-98%. The purity
of the isolated hematopoietic progenitor cells can be confirmed
by flow cytometry or fluorescence microscopy using an anti-
body recognizing an epitope different from that recongnized
by the CD34 monoclonal antibody. 
AC133+ cells have been known as primitive cells like
CD34+ cells. The CD34-cell fraction can contain primitive
cells such as AC133+ cells. However, the CD34 antigen dis-
appears as the differentiation process progresses (16, 17),
CD34- cells rarely include the AC133+ cells. This might
explain the observation of why no newly formed cardiac tis-
sue in CD34-cell transplanted hearts in this study. However,
incorporation of other immunocytochemical stains might show
CD34-cells can differentiate into cardiomyocytes. And also
some studies reported that CD34+ and AC133+ stem cells
can efficiently be isolated to a high purity from GCSF-mobi-
lized blood cells (18, 19), and whether CD34-/AC133+cells
can be mobilized using GCSF needs to be determined by fur-
ther studies.
A previous study described that functional gap junctions
exist between immature CD34+ cells and stromal cells of
the microenvironment, and thus may provide an important
regulatory pathway in hematopiesis. Further studies are needed
to evaluate gap junctions between myocardial cells and trans-
planted CD34+cells.
This study suggests that CD34+cells transplantation may
be a feasible strategy in the management of MI. The number
of circulating CD34+ cells may increase significantly, and
much more CD34+ cells could be harvested for cell trans-
plantation after GCSF administration in patients with MI.
The transplantation of CD34+ cells isolated from peripheral
blood may successfully repopulate the ischemic myocardium.
Therefore, CD34+cell transplantation at the time of coronary
artery bypass grafting could reduce scar production, restore
the ventricular function of the infarcted region, and ultimately
reduce post-infarction mortality and morbidity.
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